Long title
A phase I, ascending dose, to evaluate safety and efficacy of ADP A2M4CD8 in HLA-A2+ patients with MAGE-A4 psoitives tumors
Date receipt dossier
EU record number
ADP-0055-001
EudraCT number
2019-001965-34
Company / Sponsor
Adaptimmune LLC
Phase
I
Treated organism
Humans
Indication category
Cancer therapy
Disease
MAGE-A4 positive tumors
Therapeutic approach
Immunotherapy
Genetic modification
MAGE-A4 specific T cell receptor (TCR) with a CD8α co-receptor
Method of transfer of nucleic acid of interest
Lentiviral vectors
Administered biological material
Autologous T cells transduced with lentiviral vectors expressing a MAGE-A4 specific T cell receptor (TCR) with a CD8α co-receptor.
Route of administration
Intravenous
Locations in Belgium
Cliniques Universitaires Saint-Luc; UZ Antwerpen; U Gent
Type of procedure
Contained use only
Current status
Authorized
Pharmaceutical study code
A2M4CD8